All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

afatinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
tyrosine kinase inhibitors	4318	850140-72-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: afatinib tovok afatinib dimaleate gilotrif BIBW2992 afatinib maleate	A quinazoline and butenamide derivative that acts as a tyrosine kinase inhibitor of epidermal growth factor receptors (ERBB RECEPTORS) and is used in the treatment of metastatic NON-SMALL CELL LUNG CANCER. Molecular weight: 485.94 Formula: C24H25ClFN5O3 CLOGP: 4.34 LIPINSKI: 0 HAC: 8 HDO: 2 TPSA: 88.61 ALOGS: -4.58 ROTB: 8 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
40	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Hosey CM, Chan R, Benet LZ
S (Water solubility)	14.36 mg/mL	Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	3.369		Moderate	0.69
caco2-efflux	Caco-2 efflux ratio (BA/AB)	11.912		Moderate	0.69
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	8.128	10^-6 cm/s	Moderate	0.69
dh-clint	Dog hepatocyte intrinsic clearance	4.395	uL/min/10^6 cells	Moderate	0.69
dppb	Dog plasma protein binding (% unbound)	12.200	%	Moderate	0.69
fcs-ppb	Fetal calf serum protein binding (% unbound)	26.640	%	Moderate	0.69
herg	hERG pIC50	5.296	pIC50	Moderate	0.69
hh-clint	Human hepatocyte intrinsic clearance	2.377	uL/min/10^6 cells	Moderate	0.69
hlm-clint	Human liver microsomal intrinsic clearance	13.397	uL/min/mg protein	Moderate	0.69
hppb	Human plasma protein binding (% unbound)	9.400	%	Moderate	0.69
kinase-safety-class	ABL1,ABL2,ACVR2B,AKT3,ALK,AURKA,AXL,BLK,BMX,BRAF,BTK,CAMK2B,CAMK2D,CSF1R,CSK,DDR1,DYRK1B,EGFR,EIF2AK3,EPHA2,EPHB4,ERBB2,ERBB4,FGFR1,FLT1,FLT3,FYN,GAK,INSR,IRAK1,ITK,JAK1,KDR,KIT,LCK,LYN,MAP3K1,MAP3K10,MAP3K21,MAP4K2,MAP4K5,MAPK10,MAPK11,MAPK14,MAPK7,MAPKAPK2,MARK4,MET,MKNK1,MKNK2,NTRK1,PAK4,PDK1,PDK2,PDK4,PRKCD,PRKDC,PTK6,RET,RIPK3,SIK2,SIK3,SRC,STK33,SYK,TEK,TTK,YES1	68
kinase-selectivity-class	BLK,BRAF,CAMK2D,DDR1,EGFR,EPHB4,ERBB2,ERBB4,FLT3,GAK,IRAK4,KDR,KIT,LCK,LYN,MET,MKNK1,MKNK2,PDK4,SRC,YES1	21
mdck-mdr1-bcrp-efflux	MDCK-MDR1-BCRP efflux ratio	32.885		High	1
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	29.854		Moderate	0.69
mh-clint	Mouse hepatocyte intrinsic clearance	8.453		Moderate	0.69
mppb	Mouse plasma protein binding (% unbound)	6		Moderate	0.69
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	40.365		Moderate	0.69
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	13.220	%	Moderate	0.69
rat-kpuu-brain	Rat brain Kpuu	0.016	%	High	1
rh-clint	Rat hepatocyte intrinsic clearance	6.166	uL/min/10^6 cells	Moderate	0.69
rh-fuinc	Rat hepatocyte fraction unbound in incubation	31.970	%	Moderate	0.69
rppb	Rat plasma protein binding (% unbound)	8.830	%	Moderate	0.69
solubility-dd	Solubility at pH 7.4 in DMSO	72.611	uM	Moderate	0.69

Approvals:

Date	Agency	Company	Orphan
Sept. 25, 2013	EMA
July 12, 2013	FDA	BOEHRINGER INGELHEIM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	2109.37	27.67	674	9007	106196	90512570
Diarrhoea	1345.93	27.67	959	8722	938231	89680535
Paronychia	801.54	27.67	183	9498	7823	90610943
Metastases to central nervous system	377.57	27.67	119	9562	17423	90601343
Dermatitis acneiform	241.59	27.67	67	9614	6287	90612479
Rash	233.92	27.67	350	9331	795750	89823016
Stomatitis	208.92	27.67	197	9484	274501	90344265
Metastases to meninges	196.92	27.67	51	9630	3684	90615082
Dehydration	174.20	27.67	153	9528	194294	90424472
Decreased appetite	173.80	27.67	207	9474	376333	90242433
Skin toxicity	158.36	27.67	49	9632	6730	90612036
EGFR gene mutation	131.22	27.67	24	9657	326	90618440
Drug resistance	115.40	27.67	59	9622	30390	90588376
Acne	107.34	27.67	55	9626	28452	90590314
Pleural effusion	103.90	27.67	90	9591	111901	90506865
Acquired gene mutation	95.06	27.67	23	9658	1256	90617510
Mucosal inflammation	87.52	27.67	62	9619	57563	90561203
Death	86.82	27.67	166	9515	456385	90162381
Dry skin	80.08	27.67	70	9611	88003	90530763
Metastases to bone	75.69	27.67	42	9639	25463	90593303
Disease progression	75.09	27.67	88	9593	156527	90462239
Metastases to liver	70.93	27.67	42	9639	28765	90590001
Therapy partial responder	70.11	27.67	38	9643	22005	90596761
Vomiting	66.02	27.67	209	9472	788084	89830682
Small cell lung cancer	63.68	27.67	18	9663	1806	90616960
Metastases to lung	63.53	27.67	32	9649	15959	90602807
Skin disorder	61.59	27.67	42	9639	36664	90582102
Skin fissures	58.30	27.67	33	9648	20776	90597990
Interstitial lung disease	54.42	27.67	53	9628	76352	90542414
Arthralgia	48.20	27.67	12	9669	778510	89840256
Neoplasm progression	47.91	27.67	39	9642	44447	90574319
Nausea	45.01	27.67	235	9446	1110081	89508685
Epistaxis	44.41	27.67	50	9631	85075	90533691
Pneumonitis	39.90	27.67	35	9646	44135	90574631
Gene mutation	39.83	27.67	13	9668	2117	90616649
Small cell carcinoma	39.71	27.67	8	9673	185	90618581
Onychoclasis	39.07	27.67	18	9663	7381	90611385
Oral pain	38.06	27.67	30	9651	32653	90586113
Non-small cell lung cancer	37.49	27.67	15	9666	4366	90614400
Cutaneous symptom	36.80	27.67	9	9672	514	90618252
Condition aggravated	33.46	27.67	11	9670	595534	90023232
Blood creatinine increased	32.89	27.67	47	9634	101339	90517427
Metastasis	32.62	27.67	15	9666	6122	90612644
Prerenal failure	31.97	27.67	11	9670	2104	90616662
Pain	31.67	27.67	36	9645	996305	89622461
Rash pustular	31.65	27.67	16	9665	8033	90610733
Joint swelling	30.63	27.67	8	9673	503292	90115474
Dysgeusia	29.34	27.67	32	9649	52528	90566238
Hypersensitivity	28.10	27.67	7	9674	454670	90164096

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	1434.69	32.72	518	4546	107882	42508389
Diarrhoea	630.86	32.72	478	4586	460371	42155900
Paronychia	367.30	32.72	88	4976	4167	42612104
Metastases to central nervous system	281.19	32.72	86	4978	10269	42606002
Rash	262.01	32.72	234	4830	276720	42339551
Stomatitis	229.19	32.72	114	4950	50215	42566056
EGFR gene mutation	124.90	32.72	22	5042	212	42616059
Dermatitis acneiform	119.59	32.72	42	5022	7697	42608574
Interstitial lung disease	95.35	32.72	77	4987	78385	42537886
Decreased appetite	86.10	32.72	110	4954	193027	42423244
Skin toxicity	59.13	32.72	24	5040	6525	42609746
Metastases to meninges	56.19	32.72	17	5047	1944	42614327
Metastases to bone	54.10	32.72	29	5035	14780	42601491
Lymphangiosis carcinomatosa	52.40	32.72	14	5050	1023	42615248
Pleural effusion	50.67	32.72	60	5004	97106	42519165
Acne	50.63	32.72	27	5037	13617	42602654
Dehydration	46.84	32.72	70	4994	141697	42474574
Drug resistance	44.48	32.72	35	5029	34213	42582058
Acquired gene mutation	42.29	32.72	13	5051	1567	42614704
Therapy partial responder	41.03	32.72	27	5037	19994	42596277
Disease progression	33.95	32.72	61	5003	143595	42472676
Nail disorder	33.54	32.72	12	5052	2315	42613956

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	3054.74	25.72	1037	12431	173530	110402301
Diarrhoea	1690.87	25.72	1253	12215	1138252	109437579
Paronychia	1043.39	25.72	247	13221	10834	110564997
Metastases to central nervous system	504.43	25.72	163	13305	22654	110553177
Rash	427.35	25.72	510	12958	820454	109755377
Stomatitis	359.00	25.72	282	13186	269960	110305871
Dermatitis acneiform	348.33	25.72	107	13361	12588	110563243
EGFR gene mutation	259.49	25.72	47	13421	523	110575308
Decreased appetite	220.86	25.72	280	13188	475566	110100265
Metastases to meninges	201.03	25.72	57	13411	5071	110570760
Skin toxicity	195.97	25.72	68	13400	11715	110564116
Dehydration	169.92	25.72	189	13279	279322	110296509
Drug resistance	143.58	25.72	88	13380	56286	110519545
Acne	130.33	25.72	69	13399	33451	110542380
Pleural effusion	128.77	25.72	132	13336	177577	110398254
Interstitial lung disease	128.19	25.72	118	13350	139216	110436615
Metastases to bone	120.34	25.72	64	13404	31308	110544523
Acquired gene mutation	118.81	25.72	33	13435	2721	110573110
Therapy partial responder	113.03	25.72	65	13403	36996	110538835
Metastases to liver	97.20	25.72	58	13410	35328	110540503
Small cell lung cancer	91.49	25.72	28	13440	3244	110572587
Lymphangiosis carcinomatosa	81.31	25.72	24	13444	2458	110573373
Dry skin	79.79	25.72	81	13387	107572	110468259
Mucosal inflammation	78.02	25.72	76	13392	96065	110479766
Disease progression	74.72	25.72	118	13350	243916	110331915
Metastases to lung	74.47	25.72	42	13426	23021	110552810
Death	66.27	25.72	211	13257	698658	109877173
Gene mutation	65.65	25.72	22	13446	3407	110572424
Vomiting	64.01	25.72	249	13219	910426	109665405
Skin fissures	56.73	25.72	36	13432	24422	110551409
Skin disorder	52.90	25.72	43	13425	42870	110532961
Rash pustular	51.53	25.72	27	13441	12802	110563029
Arthralgia	48.93	25.72	17	13451	779615	109796216
Nausea	46.88	25.72	283	13185	1235407	109340424
Neoplasm progression	46.74	25.72	48	13420	64547	110511284
Cutaneous symptom	44.66	25.72	12	13456	873	110574958
Small cell carcinoma	44.43	25.72	10	13458	347	110575484
Epistaxis	41.18	25.72	64	13404	130308	110445523
Malignant neoplasm of pleura	38.46	25.72	8	13460	190	110575641
Condition aggravated	38.22	25.72	21	13447	734815	109841016
Gastrointestinal toxicity	37.89	25.72	21	13447	11127	110564704
Pneumonitis	36.81	25.72	46	13422	76485	110499346
Metastasis	34.92	25.72	18	13450	8249	110567582
Metastases to pleura	34.65	25.72	12	13456	2051	110573780
Onychoclasis	34.20	25.72	17	13451	7220	110568611
Lung adenocarcinoma	32.52	25.72	18	13450	9513	110566318
Pain	31.73	25.72	42	13426	954913	109620918
Nail disorder	31.40	25.72	37	13431	57898	110517933
Hypertension	30.48	25.72	12	13456	510072	110065759
Dysgeusia	30.40	25.72	40	13428	69945	110505886
Cheilitis	30.22	25.72	15	13453	6350	110569481
Metastases to spine	29.62	25.72	14	13454	5329	110570502
Blood creatinine increased	29.14	25.72	67	13401	182822	110393009
Prerenal failure	28.83	25.72	13	13455	4446	110571385
Hypersensitivity	28.62	25.72	7	13461	403991	110171840
Product dose omission issue	28.53	25.72	3	13465	321779	110254052
Nail bed infection	27.60	25.72	6	13462	177	110575654
Product use issue	27.39	25.72	3	13465	311692	110264139
Malignant pleural effusion	26.68	25.72	12	13456	4081	110571750
Malignant transformation	26.12	25.72	9	13459	1516	110574315

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01EB03	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
FDA MoA	N0000175076	Protein Kinase Inhibitors
MeSH PA	D000092004	Tyrosine Kinase Inhibitors
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D047428	Protein Kinase Inhibitors
FDA EPC	N0000175605	Kinase Inhibitor
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:38637	tyrosine kinase inhibitor

Related Drugs by ATC class:

L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors 8 drugs

dacomitiniberlotinibgefitinibicotiniblazertinibmobocertinibolmutinibosimertinib

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Non-small cell lung cancer, positive for epidermal growth factor receptor expression	indication	426964009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.1	acidic
pKa2	8.94	Basic
pKa3	4.09	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 20MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	9539258	Nov. 9, 2026	TREATMENT OF PATIENTS WITH ADVANCED (METASTATIC) NON-SMALL CELL LUNG CANCER WHOSE DISEASE PROGRESSED DURING OR AFTER PLATINUM-BASED CHEMOTHERAPY
EQ 30MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	9539258	Nov. 9, 2026	TREATMENT OF PATIENTS WITH ADVANCED (METASTATIC) NON-SMALL CELL LUNG CANCER WHOSE DISEASE PROGRESSED DURING OR AFTER PLATINUM-BASED CHEMOTHERAPY
EQ 40MG BASE	GILOTRIF	BOEHRINGER INGELHEIM	N201292	July 12, 2013	RX	TABLET	ORAL	9539258	Nov. 9, 2026	TREATMENT OF PATIENTS WITH ADVANCED (METASTATIC) NON-SMALL CELL LUNG CANCER WHOSE DISEASE PROGRESSED DURING OR AFTER PLATINUM-BASED CHEMOTHERAPY

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Receptor tyrosine-protein kinase erbB-4	Kinase	Q15303	ERBB4_HUMAN	INHIBITOR	Kd	8.20		CHEMBL	CHEMBL
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN	INHIBITOR	Kd	8.30		CHEMBL	CHEMBL
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN	INHIBITOR	Kd	10		CHEMBL	CHEMBL
Proto-oncogene tyrosine-protein kinase Src	Kinase	P12931	SRC_HUMAN		Kd	5.55		CHEMBL
Tyrosine-protein kinase Lck	Kinase	P06239	LCK_HUMAN		Kd	6.24		CHEMBL
Receptor-type tyrosine-protein kinase FLT3	Kinase	P36888	FLT3_HUMAN		Kd	5.85		CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret	Kinase	P07949	RET_HUMAN		IC50	5.44		CHEMBL
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Kinase	P15735	PHKG2_HUMAN		Kd	6.33		CHEMBL
Myosin light chain kinase, smooth muscle	Kinase	Q15746	MYLK_HUMAN		Kd	4.50		CHEMBL
Tyrosine-protein kinase HCK	Kinase	P08631	HCK_HUMAN		Kd	5.66		CHEMBL
Mitogen-activated protein kinase 10	Kinase	P53779	MK10_HUMAN		Kd	5.70		CHEMBL
Hepatocyte growth factor receptor	Kinase	P08581	MET_HUMAN		Kd	5.66		CHEMBL
Tyrosine-protein kinase Lyn	Kinase	P07948	LYN_HUMAN		IC50	6.13		CHEMBL
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform	Kinase	Q16816	PHKG1_HUMAN		Kd	5.89		CHEMBL
Serine/threonine-protein kinase 10	Kinase	O94804	STK10_HUMAN		Kd	5.37		CHEMBL
Mitogen-activated protein kinase 11	Kinase	Q15759	MK11_HUMAN		Kd	5.55		CHEMBL
Serine/threonine-protein kinase 17A	Kinase	Q9UEE5	ST17A_HUMAN		Kd	5.64		CHEMBL
Ephrin type-A receptor 6	Kinase	Q9UF33	EPHA6_HUMAN		Kd	6.47		CHEMBL
Casein kinase I isoform epsilon	Kinase	P49674	KC1E_HUMAN		Kd	5.89		CHEMBL
Mitogen-activated protein kinase 14	Kinase	Q16539	MK14_HUMAN		Kd	5.89		CHEMBL
Tyrosine-protein kinase FRK	Kinase	P42685	FRK_HUMAN		Kd	5.85		CHEMBL
Cyclin-G-associated kinase	Kinase	O14976	GAK_HUMAN		Kd	7.10		CHEMBL
Receptor-interacting serine/threonine-protein kinase 2	Kinase	O43353	RIPK2_HUMAN		Kd	5.57		CHEMBL
STE20-like serine/threonine-protein kinase	Kinase	Q9H2G2	SLK_HUMAN		Kd	5.43		CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 2	Kinase	Q9HBH9	MKNK2_HUMAN		Kd	5.80		CHEMBL
Mitogen-activated protein kinase 9	Kinase	P45984	MK09_HUMAN		Kd	5.68		CHEMBL
MAP kinase-activated protein kinase 2	Kinase	P49137	MAPK2_HUMAN		Kd	6.09		CHEMBL
Tyrosine-protein kinase receptor UFO	Kinase	P30530	UFO_HUMAN		Kd	5.28		CHEMBL
Ribosomal protein S6 kinase alpha-6	Kinase	Q9UK32	KS6A6_HUMAN		Kd	5.51		CHEMBL
Tyrosine-protein kinase TXK	Kinase	P42681	TXK_HUMAN		Kd	5.51		CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Kinase	Q9Y463	DYR1B_HUMAN		Kd	5.55		CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 1	Kinase	Q9BUB5	MKNK1_HUMAN		Kd	5.74		CHEMBL
Tyrosine-protein kinase Blk	Kinase	P51451	BLK_HUMAN		Kd	6.66		CHEMBL
Citron Rho-interacting kinase	Kinase	O14578	CTRO_HUMAN		Kd	5.54		CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Kinase	Q13627	DYR1A_HUMAN		Kd	6.01		CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 2	Kinase	Q92630	DYRK2_HUMAN		Kd	5.74		CHEMBL
Ephrin type-B receptor 6	Kinase	O15197	EPHB6_HUMAN		Kd	5.51		CHEMBL
Homeodomain-interacting protein kinase 4	Kinase	Q8NE63	HIPK4_HUMAN		Kd	6.44		CHEMBL
Interleukin-1 receptor-associated kinase 1	Kinase	P51617	IRAK1_HUMAN		Kd	6.62		CHEMBL
Receptor tyrosine-protein kinase erbB-3	Kinase	P21860	ERBB3_HUMAN		Kd	5.35		CHEMBL
Serine/threonine-protein kinase SBK1	Kinase	Q52WX2	SBK1_HUMAN		Kd	5.32		CHEMBL
Macrophage-stimulating protein receptor	Kinase	Q04912	RON_HUMAN		IC50	5.27		CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5	Kinase	Q13163	MP2K5_HUMAN		Kd	5.89		CHEMBL
Adenosine kinase	Kinase	P55263	ADK_HUMAN		Kd	5.46		CHEMBL
Tyrosine-protein kinase ABL1	Kinase	P00519	ABL1_HUMAN		Kd	6.64		CHEMBL

External reference:

ID	Source
4032662	VUID
N0000188388	NUI
D09724	KEGG_DRUG
4032662	VANDF
4032663	VANDF
C2987648	UMLSCUI
CHEBI:61390	CHEBI
0WM	PDB_CHEM_ID
CHEMBL1173655	ChEMBL_ID
CHEMBL2105712	ChEMBL_ID
D000077716	MESH_DESCRIPTOR_UI
DB08916	DRUGBANK_ID
5667	IUPHAR_LIGAND_ID
9230	INN_ID
850140-73-7	SECONDARY_CAS_RN
41UD74L59M	UNII
10184653	PUBCHEM_CID
1430268	RXNORM
204142	MMSL
29566	MMSL
d08113	MMSL
015117	NDDF
015118	NDDF
703579002	SNOMEDCT_US
703580004	SNOMEDCT_US
703582007	SNOMEDCT_US
41UD74L59M	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Gilotrif	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0137	TABLET, FILM COATED	30 mg	ORAL	NDA	30 sections
Gilotrif	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0138	TABLET, FILM COATED	40 mg	ORAL	NDA	30 sections
Gilotrif	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0141	TABLET, FILM COATED	20 mg	ORAL	NDA	30 sections